A tech approach to a long-term cardiovascular care 

Cardiovascular Disease (CVD) was flagged by the NHS as the most prominent condition in which lives could be saved – with plans of preventing 150,000 heart attacks over a decade. What does the technology look like which can achieve this?

The 2019 long-term plan from the NHS was clear in its intentions to prevent thousands of heart attacks, via health technology which can enable early detection, and  increasing access to testing in primary care.

Numbers are expected to reduce by improving early detection and treatment of CVD, supporting people with heart failure (HF) and heart valve disease through increased access to testing in primary care.

2022 – Still work to be done 

Fast forward to 2022, and current technology used in primary care, (the 12-Lead ECG), provides “limited diagnostic evidence” for many common heart problems

Testament to these limitations, medical malpractice claims reveal that in over 70% of all “failure to diagnose” claims, the ECG relied upon by the Healthcare Practitioner was “inconclusive” or “non-diagnostic. 

All too often these findings are incorrectly interpreted as a “Normal ECG”, rather than as a disease ECG is not designed to detect. Few patients are aware of these limitations. Cardio-HART can address this unmet need.

Breakthrough cardio tech & AI

Cardio-HART is a medical innovation that overcomes those limitations by combining the diagnostic capabilities of an AI reported 12 Lead ECG, an eStethoscope and an Echocardiogram. 

Using novel bio-signals, CHART findings cover ~95% of all common heart diseases, and its severity, including: heart failure (HFpEF, HFmrEF or HFrEF), and related structural (atrial and ventricular enlargement), functional (systolic and diastolic dysfunction) and valve abnormalities (stenosis or regurgitation). 

The AI allows it to reach significantly higher sensitivity and specificity, with a capability for the early detection of CVD onset.  

Unlike ECG, CHART can also prioritise patients based on severity.

This will dramatically change the pathway to secondary care from first come first served, to highest priority. Implementation of this new pathway will lead to more immediate access to treatment,  and of high importance and impact, realise reductions in wait times and backlogs for echocardiography services in particular, and the associated secondary care costs.

Assisting heart failure patients 

A patient seeing their doctor will undergo 3+ months of costly and time consuming testing before a clinical diagnosis of heart failure is made. 

Then another three-t0-six month wait for echocardiography, to confirm and also test for valve disease present in 60% of cases of heart failure. Lastly, the cardiologist, and access to treatment.

Now imagine that CHART can detect both Heart Failure and Valve Disease on Day-1, when the patient first saw their doctor.  

Access to treatment is immediate, or if urgent, sent to the front of the line to cardiology. Treatment would have started ~1-year earlier, reducing suffering and costs.

Don’t miss…

What’s next for preventive cardiology?